title: A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer.
abstract: BACKGROUND
  Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments.
  
  
  METHODS
  A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued.
  
  
  CONCLUSIONS
  We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy.
authors: Nobuhisa
authors: N
authors: Matsuhashi
authors: Takao
authors: T
authors: Takahashi
authors: Kenichi
authors: K
authors: Nonaka
authors: Kengo
authors: K
authors: Ichikawa
authors: Kazunori
authors: K
authors: Yawata
authors: Toshiyuki
authors: T
authors: Tanahashi
authors: Hisashi
authors: H
authors: Imai
authors: Yoshiyuki
authors: Y
authors: Sasaki
authors: Yoshihiro
authors: Y
authors: Tanaka
authors: Naoki
authors: N
authors: Okumura
authors: Kazuya
authors: K
authors: Yamaguchi
authors: Shinji
authors: S
authors: Osada
authors: Surgical Oncology, Gifu University School of Medicine, 1-1 Yanagido, Gifu City 501-1194, Japan. kyoshida@gifu-u.ac.jp.
authors: Kazuhiro
authors: K
authors: Yoshida
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004151:Dipeptides / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D000077544:Panitumumab; D011379:Prognosis; D012871:Skin Diseases / Q000139:chemically induced / Q000188:drug therapy*; D014631:Valerates / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D004151:Dipeptides; D014631:Valerates; C578860:arginyl-glutamine; C004961:beta-hydroxyisovaleric acid; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors